| Code | CSB-RA025857MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Pritumumab, targeting vimentin (VIM), a type III intermediate filament protein that serves as a key structural component of the cytoskeleton. Vimentin plays critical roles in maintaining cell integrity, supporting cellular architecture, and facilitating cell migration and adhesion. As a mesenchymal marker, vimentin is widely expressed in cells of mesenchymal origin and becomes upregulated during epithelial-mesenchymal transition (EMT), a process implicated in cancer metastasis, fibrosis, and wound healing. Aberrant vimentin expression has been associated with various malignancies, including glioblastoma, brain tumors, and other aggressive cancers, where it correlates with increased invasiveness and poor prognosis.
Pritumumab was originally developed as a therapeutic antibody targeting cell-surface vimentin on tumor cells, particularly in brain cancer research. This biosimilar antibody provides researchers with a valuable tool for investigating vimentin's roles in cancer biology, EMT mechanisms, tumor progression, and metastatic processes. It supports studies examining cytoskeletal dynamics, cell motility, and the molecular pathways underlying malignant transformation.
There are currently no reviews for this product.